Payment overview · 2025
General Payments
$240.27
6 reported records · 4 companies
Healthcare provider profile · identity verified
Paula Jean Boyle, MD
Allopathic & Osteopathic Physicians|Family Medicine · YOUNG HARRIS, GA · NPI 1972506012
Verified facts
What the public records show
CMS Open Payments records show Paula Jean Boyle, MD received $240.27 in general payments during 2025 across 6 reported records.
Stryker Corporation accounted for 61.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Stryker Corporation | Unresolved — no canonical attribution shown | $147.35 | 61.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $56.85 | 23.7% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $20.47 | 8.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.60 | 6.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $240.27 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $147.35 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $147.35 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $41.35 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $20.47 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.60 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 101 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
101 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 571 | 143 |
| Atorvastatin Calcium | Atorvastatin Calcium | 415 | 117 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 314 | 85 |
| Amlodipine Besylate | Amlodipine Besylate | 312 | 83 |
| Losartan Potassium | Losartan Potassium | 275 | 77 |
| Lisinopril | Lisinopril | 264 | 71 |
| Omeprazole | Omeprazole | 209 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 183 | 46 |
| Gabapentin | Gabapentin | 175 | 45 |
| Alprazolam | Alprazolam | 174 | 38 |
| Trazodone Hcl | Trazodone Hcl | 163 | 40 |
| Meloxicam | Meloxicam | 158 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 148 | 42 |
| Tramadol Hcl | Tramadol Hcl | 147 | 46 |
| Methylprednisolone | Methylprednisolone | 131 | 103 |
| Simvastatin | Simvastatin | 128 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 127 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 123 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 123 | 35 |
| Famotidine | Famotidine | 122 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 119 | 29 |
| Sertraline Hcl | Sertraline Hcl | 117 | 28 |
| Potassium Chloride | Potassium Chloride | 116 | 31 |
| Montelukast Sodium | Montelukast Sodium | 109 | 23 |
| Metformin Hcl | Metformin Hcl | 107 | 32 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 105 | 27 |
| Ozempic | Semaglutide | 101 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 96 | 26 |
| Metformin Hcl Er | Metformin Hcl | 86 | 27 |
| Lorazepam | Lorazepam | 83 | 20 |
| Carvedilol | Carvedilol | 80 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 80 | 18 |
| Synthroid | Levothyroxine Sodium | 79 | 19 |
| Bupropion Xl | Bupropion Hcl | 77 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 75 | 25 |
| Azithromycin | Azithromycin | 73 | 69 |
| Furosemide | Furosemide | 73 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 72 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 70 | 21 |
| Allopurinol | Allopurinol | 68 | 18 |
| Estradiol | Estradiol | 68 | 19 |
| Clonazepam | Clonazepam | 66 | 15 |
| Cefuroxime | Cefuroxime Axetil | 64 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 18 |
| Jardiance | Empagliflozin | 61 | 15 |
| Eliquis | Apixaban | 60 | 15 |
| Buspirone Hcl | Buspirone Hcl | 56 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 55 | 12 |
| Prednisone | Prednisone | 54 | 46 |
| Amitriptyline Hcl | Amitriptyline Hcl | 53 | 13 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 52 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 52 | 40 |
| Bupropion Hcl Sr | Bupropion Hcl | 50 | 12 |
| Ezetimibe | Ezetimibe | 50 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 50 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 49 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | 18 |
| Acyclovir | Acyclovir | 48 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 47 | 18 |
| Glimepiride | Glimepiride | 46 | 13 |
| Ibandronate Sodium | Ibandronate Sodium | 46 | 12 |
| Mounjaro | Tirzepatide | 46 | suppressed |
| Cefdinir | Cefdinir | 45 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 45 | suppressed |
| Fluconazole | Fluconazole | 45 | 22 |
| Atenolol | Atenolol | 43 | suppressed |
| Spironolactone | Spironolactone | 42 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 33 |
| Lovastatin | Lovastatin | 40 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 28 |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 26 |
| Finasteride | Finasteride | 36 | 11 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 35 | 34 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Valsartan | Valsartan | 34 | suppressed |
| Trulicity | Dulaglutide | 33 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 32 | 22 |
| Progesterone | Progesterone, Micronized | 31 | suppressed |
| Topiramate | Topiramate | 31 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 30 | 27 |
| Estradiol (Twice Weekly) | Estradiol | 29 | suppressed |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | 14 |
| Nystatin | Nystatin | 27 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 17 |
| Risperidone | Risperidone | 27 | suppressed |
| Rybelsus | Semaglutide | 27 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 26 | 17 |
| Cephalexin | Cephalexin | 26 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 25 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 19 |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 12 |
| Temazepam | Temazepam | 24 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Colchicine | Colchicine | 23 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 23 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 21 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Testosterone | Testosterone | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 14 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Epinephrine | Epinephrine | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Viibryd | Vilazodone Hcl | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $240.27 · 6 records | Stryker Corporation | CT THROMBECTOMY SYSTEM KIT, FLOWTRIEVER CATHETER, S, INSPIRE, Ozempic, Rybelsus, VOQUEZNA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error